본문으로 건너뛰기
← 뒤로

Assessment circulating micro-RNA-192 in Egyptian patients with non-viral liver cirrhosis and hepatocellular carcinoma.

1/5 보강
Discover oncology 📖 저널 OA 95.2% 2022: 2/2 OA 2023: 3/3 OA 2024: 36/36 OA 2025: 546/546 OA 2026: 298/344 OA 2022~2026 2026 Vol.17(1) p. 153
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
92 participants were allocated into four equal groups (n = 23): control, compensated liver cirrhosis, decompensated cirrhosis, and HCC groups.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[RESULTS] Decompensated cirrhosis and HCC showed significantly elevated Serum Alanine aminotransferase, aspartate aminotransferase, bilirubin, alpha-fetoprotein, and microRNA-192. [CONCLUSION] Serum microRNA-192 can predict decompensated liver cirrhosis and HCC with high sensitivity and specificity.

Abdelaziz MA, Elagali AM, Soliman AS, Sakr HI, Ibrahim AA, Huzien AH, Abujamai JZ, Damanhory AA, Gaber SS

📝 환자 설명용 한 줄

[BACKGROUND] It is challenging to diagnose hepatic cirrhosis and hepatocellular carcinoma (HCC) at an early stage since non-invasive markers are not specific and do not identify the early stage.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 23

이 논문을 인용하기

↓ .bib ↓ .ris
APA Abdelaziz MA, Elagali AM, et al. (2026). Assessment circulating micro-RNA-192 in Egyptian patients with non-viral liver cirrhosis and hepatocellular carcinoma.. Discover oncology, 17(1), 153. https://doi.org/10.1007/s12672-025-04304-2
MLA Abdelaziz MA, et al.. "Assessment circulating micro-RNA-192 in Egyptian patients with non-viral liver cirrhosis and hepatocellular carcinoma.." Discover oncology, vol. 17, no. 1, 2026, pp. 153.
PMID 41575695 ↗

Abstract

[BACKGROUND] It is challenging to diagnose hepatic cirrhosis and hepatocellular carcinoma (HCC) at an early stage since non-invasive markers are not specific and do not identify the early stage.

[OBJECTIVE] Serum microRNA-192 could represent an early and critical pathogenetic factor in different liver diseases.

[METHODS] 92 participants were allocated into four equal groups (n = 23): control, compensated liver cirrhosis, decompensated cirrhosis, and HCC groups.

[RESULTS] Decompensated cirrhosis and HCC showed significantly elevated Serum Alanine aminotransferase, aspartate aminotransferase, bilirubin, alpha-fetoprotein, and microRNA-192.

[CONCLUSION] Serum microRNA-192 can predict decompensated liver cirrhosis and HCC with high sensitivity and specificity.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기